Autopsy report · NCT04761705

Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension

“Awaiting transition to Part 2”

The sponsor’s own words in the registry.

Life of this trial

• Suspended: paused, and may or may not restart.
• 70 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 1, Phase 2

Sponsor

JeniVision, Inc.

Sponsor type

Industry

Conditions

Ocular Hypertension; Open Angle Glaucoma

Interventions

JV-GL1; Latanoprost 0.005% Ophthalmic Solution

Participants

70 (planned, not actual)

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.